Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition

Aberrant activation of the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is common in systemic lupus erythematosus (SLE), conferring immune-mediated properties in target tissues. Multiple cytokines activate different combinations of JAKs and STATs to alter th...

Full description

Bibliographic Details
Main Authors: Dionysis Nikolopoulos, Ioannis Parodis
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Medicine
Subjects:
systemic lupus erythematosus
JAK inhibitors
TYK2
treatment
small molecules
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1217147/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1217147/full

Similar Items